Article

Phytochemical Profiling, In Vitro Biological Activities, and In-Silico Studies of Ficus vasta Forssk.: An Unexplored Plant

Hanan Y. Aati 1,*,†, Mariyam Anwar 2, Jawaher Al-Qahtani 1, Areej Al-Taweel 1, Kashif-ur-Rehman Khan 2,*,†, Sultan Aati 3, Faisal Usman 4, Bilal Ahmad Ghalloo 2, Hafiz Muhammad Asif 5, Jafir Hussain Shirazi 6 and Aliza Abbasi 2

1 Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh 11495, Saudi Arabia
2 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur 63100, Pakistan
3 UWA, University of Western Australia, Nedland, WA 6009, Australia
4 Department of Pharmaceutics, Faculty of Pharmacy, Bahauddin Zakariya University, Multan 60000, Pakistan
5 Faculty of Medicine and Allied Health Sciences, University College of Conventional Medicine, The Islamia University of Bahawalpur, Bahawalpur 63100, Pakistan
6 Department of Pharmaceutics, Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur 63100, Pakistan
* Correspondence: hati@ksu.edu.pk (H.Y.A.); kashifur.rahman@iub.edu.pk (K.-u.-R.K.)
† These authors contributed equally to this work.

Abstract: Ficus vasta Forssk. (Moraceae family) is an important medicinal plant that has not been previously investigated for its phytochemical and biological potential. Phytochemical screening, total bioactive content, and GCMS analysis were used to determine its phytoconstituents profile. Antioxidant, antibacterial, antifungal, anti-viral, cytotoxicity, thrombolytic, and enzyme inhibition activities were examined for biological evaluation. The plant extract exhibited the maximum total phenolic (89.47 ± 3.21 mg GAE/g) and total flavonoid contents (129.2 ± 4.14 mg QE/g), which may be related to the higher antioxidant potential of the extract. The extract showed strong α-amylase (IC50 5 ± 0.21 µg/mL) and α-glucosidase inhibition activity (IC50 5 ± 0.32 µg/mL). Significant results were observed in the case of antibacterial, antifungal, and anti-viral activities. The F. vasta extract inhibited the growth of HepG2 cells in a dose-dependent manner. The GCMS analysis of the extract provided the preliminary identification of 28 phytocompounds. In addition, the compounds identified by GCMS were subjected to in silico molecular docking analysis in order to identify any interactions between the compounds and enzymes (α-amylase and α-glucosidase). After that, the best-docked compounds were subjected to ADMET studies which provide information on pharmacokinetics, drug-likeness, physicochemical properties, and toxicity. The present study highlighted that the ethanol extract of F. vasta has antidiabetic, antimicrobial, anti-viral, and anti-cancer potentials that can be further explored for novel drug development.

Keywords: Ficus vasta; antibacterial; anti-viral; antifungal; thrombolytic; HepG2 cell line; GCMS; molecular docking; ADMET

1. Introduction

Medicinal plants have played a major role as source of lead compounds that may be used for a variety of medicinal and pharmacological activities [1]. These plants are commonly used to treat various diseases including asthma, diabetes, respiratory, gastrointestinal, skin disorders, urinary, cardiovascular, and hepatic diseases [2]. Recently, due to the wide variety of secondary metabolites identified in medicinal plants, there has been a greater focus on research which can help to obtain lead compounds from medicinal plants [3]. Some countries have started botanical drug research projects to investigate phyto-pharmaceuticals due to the enormous therapeutic potential of plants [4]. Diabetes
is a metabolic disease that is caused by hyperglycemia due to the deficiency of insulin secretion or insulin action (or both in some cases) [5]. As the incidence of diabetes continues to rise, there is an increasing interest in plants with strong antidiabetic properties. These plants could provide a breakthrough in the fight against this disease [6]. There are many mechanisms by which antidiabetic drugs can help to regulate blood sugar levels. These include suppressing hepatic glucose production, improving the sensitivity of insulin receptors, stimulating insulin secretion, and increasing peripheral glucose uptake. In addition, antidiabetic drugs can also delay digestion and absorption of carbohydrates from the gut, helping to control post-meal blood sugar levels [7]. Recent research suggests that α-amylose and α-glucosidase inhibitors help to control blood sugar levels post-meal by delaying digestion [5]. α-Glucosidase and α-amylase inhibitors such as acarbose and miglitol inhibited the absorption of carbohydrates from the intestine [8]. There are many mechanisms by which antidiabetic drugs can help to regulate blood sugar levels. These include suppressing hepatic glucose production, improving the sensitivity of insulin receptors, stimulating insulin secretion, and increasing peripheral glucose uptake. In addition, antidiabetic drugs can also delay digestion and absorption of carbohydrates from the gut, helping to control post-meal blood sugar levels [7]. Recent research suggests that α-amylose and α-glucosidase inhibitors help to control blood sugar levels post-meal by delaying digestion [5]. α-Glucosidase and α-amylase inhibitors such as acarbose and miglitol inhibited the absorption of carbohydrates from the intestine [8]. The traditional medicinal plants are rich source of chemical constituents and phytotherapeutic preparations for the development of antidiabetic drugs [9].

Liver cancer is the second main cause of death globally [10]. Hepatocellular carcinoma causes around 90% of all primary liver cancers [11], and chemotherapy, radiation treatment, or both may be used to treat advanced liver cancer [12]. Many studies have shown that medicinal plants have compounds that can slow cancer progression [13]. Antioxidants are compounds that act as scavengers of free radicals created by the body’s cells due to various metabolic reactions and external factors. These free radicals are unstable and one of the most common causes of cancer in the human body, they cause serious damage to the proteins, lipids, DNA, and RNA [12].

Infectious diseases are a main cause of death and illness in developing countries. They are a serious public health problem that can have a devastating impact on communities [14]. There are different types of pathogenic microbes that can cause illness, including fungi, bacteria, parasites, and viruses [15]. Scientists have been prompted to seek for novel compounds with antimicrobial activity from a wide range of sources, including medicinal plants, as a result of the increase cases of multidrug-resistant (MDR) infections [16]. Plant polyphenols are known to have medicinal qualities, including antibacterial, antifungal, and anti-viral activities. This is due to the fact they can induce damage to the bacterial cell membrane, either structurally or functionally. Different studies have revealed that polyphenol-rich plants have antioxidant and antibacterial activities [17]. To effectively combat fungal illnesses, new antifungals must be developed. In this regard, interest in alternative medicinal approaches is expanding, and the use of plant extracts as antimicrobial adjuvants has gotten much attention in recent years [18]. Polyphenols are a promising area in research for developing anti-viral medications. They work in various ways, including preventing virus entrance or affecting virus replication. Polyphenols are widely available and relatively inexpensive to produce, making them an attractive option for medication development [19].

*Ficus* is a genus that belongs to the Moraceae family of woody trees, shrubs, and vines that includes roughly 800 species and 2000 variations. *Ficus* plants have long been used in traditional medicine for their wide range of therapeutic properties. Recent studies have revealed that these plants possess various biological activities, including antioxidant, anti-inflammatory, anti-cancer, antidiabetic, anti-tumor, antiproliferative, antimicrobial, antihelminthic, and hepatoprotective effects [20]. These properties make *Ficus* a promising natural therapy for many different diseases and conditions. *Ficus vasta* Forssk. is a large tree that can grow over 25 m tall. Its leaves are alternate and spirally arranged with an uneven texture. They are almost circular in shape, with an entire margin and a rounded tip, though often with a blunt point. The leaves are usually glabrescent above and below, puberulous or hirsute [21]. These are widespread in dry, arid regions of Africa, such as Sudan, Uganda, Saudi Arabia, Tanzania, and Ethiopia. The leaves and bark can be used to prepare a poultice for tumors [22]. The leaves of *F. vasta* are traditionally used to treat rheumatic diseases, intestinal worms, and muscle pains. Preliminary phytochemical analysis showed that it consists of carbohydrates, flavonoids, tannins, coumarins, and triterpenes [23]. Some
phytochemical constituents such as beta-sitosterol, lupeol, stigmasterol, and ursolic acid were isolated and identified from the ariel part of this plant [24]. Moreover, antioxidant and antibacterial activities are investigated in a hydro-methanolic extract of *F. vasta* leaves [25].

The literature review regarding *F. vasta* demonstrated that there are only few data in terms of phytochemical investigations and biological activities as compared to the other members of the genus *Ficus*. Therefore, the goal of this research was to explore the aerial parts of *F. vasta* for its phytochemical and biological activities. The therapeutic potential of *F. vasta* was assessed for the first time through its antioxidant, antibacterial, antifungal, anti-viral, cytotoxicity, and enzyme inhibitory activities. GCMS was used to identify the phytoconstituents responsible for these activities. The major phytoconstituents identified by GCMS in the ethanolic extract were further studied for in silico studies.

2. Results
   2.1. Phytochemical Analysis
      2.1.1. Preliminary Phytochemical Profiling

Phytoconstituents of *F. vasta* extract were analyzed by the phytochemical profiling tests. Table 1. showed that primary and secondary metabolites (i.e., carbohydrates, alkaloids, flavonoids, steroids, glycosides, phenols, tannins, and saponins are present in the ethanolic extract of *F. vasta*).

| Sr. No. | Metabolites       | Tests                | Results |
|---------|-------------------|----------------------|---------|
| 1       | Carbohydrates     | MolischTest          | +       |
| 1       | Carbohydrates     | Iodine Test          | +       |
| 2       | Proteins          | Biurette Test        | −       |
| 3       | Lipids            | Saponification Test  | +       |
| 4       | Flavonoids        | Reaction with NaOH   | +       |
| 5       | Tannins           | Lead Acetate Test    | +       |
| 6       | Saponins          | Frothing             | +       |
| 7       | Amino acids       | Ninhydrin Test       | −       |
| 8       | Steroids/Terpenes | Salkowski Test       | +       |
| 9       | Glycosides        | Erdmann Test         | +       |
|         |                   | Hager Test           | +       |
| 10      | Alkaloids         | Wagner Test          | +       |
|         |                   | Mayer Test           | +       |
| 11      | Phenols           | Ferric chloride Test | +       |
|         |                   | Acetic Anhydride Test| −       |
| 12      | Resins            |                      |         |

*“+” Present and “−” Absent.*

2.1.2. Total Bioactive Contents

The results of the total phenolic and flavonoid content of *F. vasta* are shown in Table 2. The TPC and TFC of *F. vasta* extract was carried out with the help of regression equation that was obtained from gallic acid and quercetin standard curve. The ethanolic extract of aerial parts of *F. vasta* showed total phenolic content of 89.47 ± 3.21mg GAE/g and total flavonoid contents of 129.2 ± 4.14mg QE/g.

| Sample | TPC mg GAE/g | TFC mg QE/g | Antioxidant Activities (mg/mL) IC_{50} |
|--------|--------------|-------------|----------------------------------------|
|        |              |             | DPPH | FRAP | ABTS | CUPRAC |
| *F. vasta* | 89.47 ± 3.21 | 129.2 ± 4.14 | 1.75 ± 0.08 | 1.91 ± 0.11 | 1.63 ± 0.06 | 1.51 ± 0.04 |

All tests were performed in triplicates and results are expressed as mean ± S.D.
2.1.3. Gas chromatography-Mass Spectroscopy Analysis

In-depth phytochemical identification, the ethanolic extract was further evaluated by GCMS. The GCMS chromatogram of *F. vasta* ethanolic extract showed 28 peaks of compounds. The GCMS chromatogram of compounds was identified by comparing their peak retention time, height (percent), and patterns of mass spectral fragmentation to those of known compounds present in the National Institute of Standards and Technology library (NIST). In GCMS, most of the compounds related to the classes like fatty acids, steroids, vitamins, and esters. Major compounds of GCMS consisting of Stigmasterol, 22,23-dihydro (8.04%), 11-Oxours-12-en-3-yl acetate (6.46%), Phytol (5.13%), n-Hexadecanoic acid (4.27%), Quinic acid (4.07%), 11,14,17-eicosatrienoic acid methyl ester (3.76%), 4-((1E)-3-Hydroxy-1-propenyl)-2-methoxyphenol (3.71%), 2,3-Dihydrobenzofuran (2.17%), and many others minor compounds. The identified compounds from ethanol extract are described in Table 3 and GCMS chromatogram is represented in Figure 1.

![GCMS chromatogram of *F. vasta* ethanolic extract.](image)

### Table 2. Total bioactive contents and antioxidant activities of *F. vasta* aerial parts

| Sample | TPC mg GAE/g | TFC µg/mL | ABTS IC₅₀ µM | DPPH IC₅₀ µM | FRAP IC₅₀ µM | CUPRAC IC₅₀ µM |
|--------|--------------|-----------|--------------|--------------|--------------|---------------|
| Sample A | 89.47 ± 3.21 | 129.2 ± 4.14 | 1.75 ± 0.08 | 1.91 ± 0.11 | 1.63 ± 0.06 | 1.51 ± 0.04 |
| Sample B | 87.34 ± 2.89 | 125.1 ± 3.98 | 1.67 ± 0.07 | 1.89 ± 0.10 | 1.59 ± 0.05 | 1.49 ± 0.03 |
| Sample C | 85.23 ± 2.78 | 121.0 ± 3.87 | 1.59 ± 0.06 | 1.87 ± 0.09 | 1.57 ± 0.04 | 1.48 ± 0.03 |

2.2. Biological Activities

#### 2.2.1. Antioxidant Activities

In this study, the antioxidant activity of *F. vasta* extract was examined by the DPPH, ABTS, FRAP, and CUPRAC, and the results are shown in Table 2. In the case of radical scavenging activities, the DPPH result suggested that the ethanolic extract of aerial parts of *F. vasta* exhibited the highest activity with IC₅₀ 1.75 mg/mL. In comparison, the ABTS result showed the activity with IC₅₀ 1.63 mg/mL. According to the reducing power assays, the FRAP and CUPRAC results showed the highest activity with IC₅₀, i.e., 1.91 mg/mL, and 1.51 mg/mL, respectively. The results of FRAP and DPPH activities of the extract suggested a direct correlation with the polyphenol content.

#### 2.2.2. Enzyme Inhibition Activities

This study used acarbose as a positive control to determine the enzyme inhibition activity. The α-glucosidase activity result showed that ethanolic extract of *F. vasta* exhibits the excellent α-glucosidase inhibitory effect with IC₅₀ 5 ± 0.32 µg/mL compared to the standard acarbose with IC₅₀ 2.59 ± 0.11 µg/mL. At the same time, the result of α-amylase activity showed that ethanolic extract of *F. vasta* showed an excellent α-amylase inhibitory effect with IC₅₀ 5 ± 0.21 µg/mL compared to the standard acarbose with IC₅₀ 41.10 ± 3.21 µg/mL. The results of α-glucosidase and α-amylase inhibition activities were shown in Figure 2.
Table 3. Phytocompounds identified in ethanolic extract of *F. vasta* by GCMS.

| Sr No. | RT (minutes) | Compounds Identified                          | M. Formula | Mol. Wt (g/mol) | Chemical Class                | Area (%) | Reported Activities of Compounds                                                                 |
|--------|--------------|-----------------------------------------------|------------|----------------|-------------------------------|----------|-----------------------------------------------------------------------------------------------|
| 1      | 6.80         | Catechol                                      | C₆H₆O₂     | 110.11         | Benzenediol                   | 0.25     | Antioxidant [26], antibacterial, and antifungal [27]                                            |
| 2      | 6.91         | 2,3-Dihydrobenzofuran                         | C₆H₈O      | 120.15         | 1-Benzofurans                 | 2.17     | Antileishmania [28]                                                                              |
| 3      | 12.20        | 4,4,5,8-Tetramethylchroman-2-ol               | C₁₃H₁₈O₂    | 206.28         | Vitamin E analog              | 1.39     | Anti-inflammatory [29]                                                                            |
| 4      | 12.74        | Levoglucosan                                  | C₆H₁₀O₃    | 162.14         | Carbohydrate                  | 0.55     | Antibacterial [30]                                                                               |
| 5      | 12.76        | Nonanoic acid                                 | C₄H₁₅O₂    | 158.24         | Ester                         | 0.58     | Antimicrobial [31], antifungal [32]                                                               |
| 6      | 12.79        | Phloroglucinol                                | C₄H₆O₃     | 126.11         | Benzene triol                 | 0.40     | Oxidative stress [33]                                                                            |
| 7      | 13.10        | 4-((1E)-3-Hydroxy-1-propenyl)-2-methoxyphenol | C₁₀H₁₂O₃   | 180.2005       | Organic compound              | 3.71     | Anti-inflammatory, antimicrobial, and antioxidant [34]                                           |
| 8      | 13.50        | Quinic acid                                   | C₇H₁₄O₆    | 192.17         | Cyclitol/Cyclohexane carboxylic acid | 4.07   | Anti-carcinogenic and antioxidant [35]                                                           |
| 9      | 15.63        | n-Hexadecanoic acid                           | C₁₆H₃₂O₆   | 256.42         | Fatty acid                    | 4.27     | Antioxidant, and nematicide [36]                                                                |
| 10     | 15.92        | Hexadecanolic acid, ethyl ester               | C₁₈H₃₆O₂   | 284.5          | Fatty acid ester              | 1.82     | Antioxidant, and nematicide [37]                                                                |
| 11     | 17.35        | 9,12,15-Octadecatrienoic acid, methyl ester, (Z,Z,Z)- | C₁₉H₃₂O₂ | 292.5          | Fatty acid ester              | 0.72     | Anti-inflammatory, anti-cancer, hepatoprotective, [38]                                           |
| 12     | 17.54        | Phytol                                        | C₂₀H₄₀O     | 296.5          | Diterpenoid                   | 5.13     | Cytotoxic, antioxidant, and antimicrobial [39,40]                                               |
| 13     | 17.67        | 16-Methylheptadecanoic acid methyl ester      | C₁₉H₃₂O₂   | 298.5          | Ester of isostearic acid      | 0.13     | Anti-cancer [41]                                                                                |
| 14     | 17.92        | 9 12-Octadecadienoic acid (z z)- methyl ester | C₁₉H₃₂O₂   | 294.4          | Fatty acid                    | 2.80     | Hepatoprotective [42]                                                                            |
| 15     | 18.03        | 11 14 17-eicosatrienoic acid methyl ester     | C₂₁H₃₄O₂   | 320.5          | Fatty acid methyl ester       | 3.76     | Anti-inflammatory, anti-arthritis [43]                                                           |
| 16     | 18.19        | Linoleic acid ethyl ester                     | C₂₀H₃₆O₂   | 308.5          | Linoleic acid                 | 0.99     | Anti-acute [44]                                                                                 |
| 17     | 18.23        | Octadecanoic acid                             | C₁₈H₃₂O₂   | 284.5          | Fatty acid (stearic acid)     | 0.43     | Antioxidant, antimicrobial [45]                                                                 |
| 18     | 22.74        | 12-Oleanene-3-yl acetate (3.α)-              | C₃₂H₅₂O₂   | 468.8          | Triterpenoid                  | 0.01     | Antioxidant and cytotoxic [46]                                                                   |
| 19     | 23.18        | Hexadecanolic acid, 2-hydroxy-1(hydroxymethyl)ethyl ester | C₁₉H₃₈O₄ | 330.5          | Fatty acid                    | 1.77     | Antioxidant, and anti-inflammatory [47]                                                          |
| 20     | 25.84        | Methyl (Z)-5,11,14,17-eicosatetraenoate       | C₂₁H₃₄O₂   | 318.5          | Fatty acid methyl ester       | 1.31     | Antibacterial [48]                                                                               |
| 21     | 32.06        | Vitamin E                                     | C₂₅H₅₀O₂   | 430.7          | Vitamins                      | 0.65     | Anti-cancer, hepatoprotective, and antispasmodic [36]                                           |
| 22     | 33.82        | Campesterol                                   | C₂₈H₄₈O     | 400.7          | Phytosterol                   | 0.83     | Anti-inflammatory, antidabetic, and anti-cancer [36]                                            |
Table 3. Cont.

| Sr No. | RT (minutes) | Compounds Identified | M. Formula       | Mol. Wt (g/mol) | Chemical Class | Area (%) | Reported Activities of Compounds                                      |
|--------|--------------|---------------------|------------------|-----------------|----------------|----------|--------------------------------------------------------------------|
| 23     | 34.56        | Stigmasterol        | C_{29}H_{48}O    | 412.7           | Sterol         | 0.90     | Anti-tumor, hypoglycemic, and anti-inflammatory [49–51]            |
| 24     | 34.65        | Ursa-9(11),12-dien-3-ol | C_{30}H_{48}O    | 424.7           | Triterpene     | 0.36     | Anti-inflammatory, and antioxidant [52]                            |
| 25     | 35.92        | beta-Sitosterol     | C_{29}H_{50}O    | 414.7           | Phytosterol    | 1.54     | Anti-cancer, and hypocholestremia [53]                              |
| 26     | 36.09        | Stigmasterol, 22,23-dihydro | C_{28}H_{50}O    | 414.7           | Steroid        | 8.04     | Anti-cancer, antioxidant, hypoglycemic, and anti-viral [54]         |
| 27     | 37.36        | 11-Oxours-12-en-3-yl acetate | C_{32}H_{52}O_{3} | 482.7           | Ester of acetic acid | 6.46     | Antidiabetic [55]                                                   |
| 28     | 36.73        | beta-Amyrin         | C_{30}H_{50}O    | 426.7           | Triterpenoid   | 2.26     | Antioxidant, antimalarial, and antiulcer [52]                       |

RT: Retention time, M. formula: Molecular formula, % Area: % peak area, and Mol. wt: Molecular weight.
2.2.3. Antibacterial Activity

The antibacterial potential of *F. vasta* was evaluated using the agar well diffusion method against five positive strains include *Bacillus subtilis, Bacillus pumilus, Staphylococcus epidermidis, Staphylococcus aureus, Micrococcus luteus*, and two negative strains including *Escherichia coli, and Bordetella bronchiseptica* and results are shown in Table 4 and Figure S3. This antibacterial potential was revealed by inhibition of growth of bacteria which was measured as zone of inhibition. The results showed that plant extract has a dose-dependent effect on bacteria. Its activity against the bacteria is lowest at low concentrations (25 mg/mL). However, antibacterial activity was observed to be higher for *S. aureus* and *E. coli*, with 22 mm and 24 mm zones of inhibition, respectively, at a concentration of 100 mg/mL.

Table 4. Antibacterial activity of *F. vasta*.

| Bacterial Strains          | Conc. 25 mg/mL | Conc. 50 mg/mL | Conc. 75 mg/mL | Conc. 100 mg/mL | Standard Ceftriaxone 1 mg/mL |
|----------------------------|----------------|----------------|---------------|----------------|-----------------------------|
| *Staphylococcus aureus*    | 18             | 20             | 21            | 22             | 26                          |
| *Staphylococcus epidermidis* | 16            | 17             | 20            | 21             | 26                          |
| *Escherichia coli*         | 20             | 21             | 22            | 24             | 25                          |
| *Bordetella bronchiseptica* | 12            | 13             | 15            | 18             | 20                          |
| *Bacillus subtilis*        | 12             | 16             | 17            | 19             | 22                          |
| *Bacillus pumilus*         | 13             | 14             | 16            | 17             | 21                          |
| *Micrococcus luteus*       | 15             | 17             | 18            | 20             | 21                          |

2.2.4. Antifungal Activity

Table 5 presented the antifungal activity of *F. vasta* extract. The results of this activity showed the maximum antifungal activity of extract was observed against fungal strain *F.avenaceum* (54.94%) followed by *F. brachygibbosum* (48.51%) and *A. niger* (42%).
Table 5. Antifungal activity of *F. vasta* by agar tube dilution method.

| Sample | Fungal Strains   | Linear Growth in Test Tubes (mm) | Linear Growth in Control (mm) | % Age Inhibition |
|--------|------------------|----------------------------------|-------------------------------|------------------|
| F. vasta | *Aspergillus niger* | 42 | 98 | 42% |
| F. vasta | *Fusariumavenaceum* | 50 | 91 | 54.94% |
| F. vasta | *Fusarium brachygibbosum* | 49 | 101 | 48.51% |

2.2.5. Anti-Viral Activity

The anti-viral potential against three strains (i.e., avian infectious bronchitis virus (IBV), influenza virus (H9), and Newcastle disease virus (NDV)) was carried out using a haemagglutination test method, and the results are tabulated in Table 6. The ethanolic extract of *F. vasta* was more active against the avian infectious bronchitis virus and Newcastle disease virus (IBV and NDV titer 0) while less effective against the influenza virus and its H9 titer was 16.

Table 6. Anti-viral activity of *F. vasta*.

| Strains | Titer Count in Control | Titer Count in Acyclovir | Titer Count in *F. vasta* |
|---------|------------------------|--------------------------|---------------------------|
| IBV     | 1024                   | 00                       | 00                        |
| NDV     | 2048                   | 00                       | 00                        |
| H9      | 2048                   | 00                       | 16                        |

IBV: avian infectious bronchitis virus, H9: Influenza virus, and NDV: Newcastle disease virus. HA titer 0 to 8: highly strong, 16 to 32: strong, 64 to 128: moderate, and 256 to 2048: not active [56].

2.2.6. Thrombolytic Activity

The results of thrombolytic activity of *F. vasta* and Streptokinase are described in Figure 3. The percentage clot lysis of ethanolic extract of *F. vasta* was $47.78 \pm 4.21\%$ while streptokinase showed $81.86 \pm 6.37\%$ clot lysis.

![Thrombolytic activity](image)

**Figure 3.** The thrombolytic activity of *F. vasta*.

2.2.7. Hemolytic Activity

Data shown in (Table 7) represented the hemolytic activity of ethanolic extract of *F. vasta*. The hemolytic % value of extract was $6.39 \pm 0.45\%$ while the value of standard was $92.27 \pm 4.71\%$. The hemolysis activity of extract was less than 30%, so extract is nontoxic and safe as food. The hemolysis activity can be performed using a wide range of methods,
which is one of its major challenges and limitations. This produces a wide range of absolute values in addition to complicates comparisons between studies [57].

Table 7. Hemolytic activity of *F. vasta* and standard Triton X-100.

| Extract/Standard | Hemolytic Activity % |
|------------------|----------------------|
| *F. vasta*       | 6.39 ± 0.45          |
| Triton X-100     | 92.27 ± 4.71         |

2.2.8. Cytotoxicity

MTT activity was used to evaluate the effect of *F. vasta* extract on HepG2 cell growth. Treatment with *F. vasta* extract for 48 h inhibited the growth of cells in a dose-dependent manner. The IC<sub>50</sub> value for this assay was 0.563 µg/mL. The outcomes of the activity are represented in Figure 4.

**Figure 4.** Cytotoxicity activity of *F. vasta*.

2.3. *In Silico* Studies

2.3.1. Molecular Docking

Molecular docking studies were conducted against all compounds that were identified by the GCMS for both α-glucosidase and α-amylase. The docking results suggested that the binding affinity of 7 compounds was higher than the binding affinity of acarbose (standard) in α-glucosidase and α-amylase. Ursa-9(11),12-dien-3-ol was the most active of all of the tested compounds, with a binding affinity of −10.5, which interacted in the active site of α-amylase by forming one H-bond interaction with ASP 197 amino acid residue at a bond distance of 2.87 angstroms. From the 2D structures of ligands with α-amylase, it was clear that beta-amyrin, Campesterol, beta-Sitosterol, and Stigmasterol showed H-bond interactions. In contrast, Olean-12-en-3-ol, acetate, (3beta)- and 11-Oxours-12-en-3-yl acetate did not show any H-bond interactions. The docking results of α-glucosidase showed that beta-amyrin exhibit the highest binding affinity of −8.4 by making H-bond interaction with GLU 113 amino acid residue with a bond distance of 2.78 angstroms. Olean-12-en-3-ol, acetate, (3beta)-, Stigmasterol, Campesterol, and beta-Sitosterol also showed H-bond interactions with binding affinity -8.1, -7.5, -6.9, and -6.9 respectively while Ursa-9(11),12-dien-3-ol and 11-Oxours-12-en-3-yl acetate didn’t show any H-bond interactions. This demonstrates *F. vasta*’s ability to inhibit α-glucosidase and α-amylase. Figures 5, 6 and S4, and Table 8 illustrate the docking results of the compounds with both receptors. The docking study was validated by superimposing the co-crystallized ligand (Acarbose) with extracted Acarbose and redocked to α-amylase (PDB: 1b2y) crystal structure and a low
RMSD of 1.525 Å was observed. Similarly, an RMSD of 1.234 Å was observed with α-glucosidase (pdb id: 3TOP). The co-crystallized Acarbose (Yellow) and extracted Acarbose (Red) are shown in Figure S5.

Figure 5. 2D structures of best-docked compound and Acarbose against α-amylase.

Figure 6. 2D structures of best-docked compound and Acarbose against α-glucosidase. The green dotted line showed the hydrogen bond, while the red showed the hydrophobic interactions.
Table 8. Binding affinity and interactions of best-docked compounds.

| Sr. No | Ligand                          | Structures | Binding Energy | Amino Acids H-Bond Interactions | Amino Acids Hydrophobic Interactions | Binding Energy | Amino Acids H-Bond Interactions | Amino Acids Hydrophobic Interactions |
|--------|--------------------------------|------------|----------------|---------------------------------|-------------------------------------|----------------|---------------------------------|-------------------------------------|
| 1      | Ursa-9(11),12-dien-3-ol        | ![Structure](image1) | −10.5          | ASP 197                         | TRP 59, HIS 101, LEU 162, TYR 62, ALA 198, TYR 62, THR 163, GLN 63, LEU 165 | −8             | -                              | PRO 223, PHE 225, LEU 219, GLU 141, GLN 392, TYR 388, LYS 290, ASP 289, TRP 288 |
| 2      | Olean-12-en-3-ol, (3beta)-     | ![Structure](image2) | −10.4          | -                               | TRP 59, GLU 233, ASP 356, HIS 305, TRP 58, ASP 300, THR 163, ASP 197, HIS 299, TYR 62, LEU 165, HIS 101 | −8.1           | LEU 287, ASN 258                 | PHE 225, GLU 226, VAL 222, PRO 214, PRO 223, GLY 286 |
| 3      | beta-Amyrin                    | ![Structure](image3) | −10.1          | GLU 233, ASP 197                | TRP 59, THR 163, ASP 300, LEU 162, TYR 62, HIS 299, TRP 58                      | −8.4           | GLU 113                         | TYR 122, PRO 109, TRP 110, GLU 183, GLU 180, TYR 68, LYS 69 |
| 4      | 11-Oxours-12-en-3-yl acetate   | ![Structure](image4) | −9.6           | -                               | TRP 58, GLU 233, ASP 197, TRP 59, LEU 162, TYR 62, THR 163                      | −8.1           | -                              | LYS 395, TYR 221, LEU 219, GLU 141, GLN 392, PRO 223, PHE 225, ASP 289, TRP 288, LYS 290, ILE 391 |
| 5      | Campesterol                    | ![Structure](image5) | −9.3           | GLU 240                         | TYR 151, HIS 299, ASP 197, LEU 162, ILE 235, ALA 198, HIS 201, TYR 62, GLU 233, TRP 59, TRP 58, LYS 200, ASP 300 | −6.9           | LYS 205                         | LYS 206, GLU 173, ASN 171, PHE 210, ILE 127, TRP 128, ASP 124, HIS 129, LYS 118, GLY 209, ALA 208 |
Table 8. Cont.

| Sr. No. | Ligand            | Structures | α-Amylase                    | α-Glucosidase                |
|---------|-------------------|------------|------------------------------|------------------------------|
|         |                   |            | Binding Energy | Amino Acids | Hydrophobic Interactions | Binding Energy | Amino Acids | Hydrophobic Interactions |
|         |                   |            |                | H-Bond Interactions |                        |                |                |                        |
| 6       | beta-Sitosterol   | ![Image](image1.png) | –9.3 | GLU 240 | ILE 235, HIS 201, TYR 62, TYR 151, HIS 299, TRP 58, ALA 198, ARG 195, ASP 197, LEU 162, TRP 59, LYS 200, GLU 233 | –6.9 | ASN 258 | LYS 290, PRO 223, PHE 225, MET 229, LEU 287, ASP 289, TRP 288, SER 145, GLU 141, ILE 143 |
| 7       | Stigmasterol      | ![Image](image2.png) | –9.1 | GLU 233 | ALA 198, TRP 59, LEU 162, ASP 197, GLU 141, GLN 63, GLN 83, GLY 104, THR 163 | –7.5 | GLN 392, LYS 395 | MET 229, PHE 225, GLU 141, PRO 223, ILE 391, SER 145, TYR 388, LYS 290, TRP 288, LEU 287 |
| 8       | Acarbose (standard) | ![Image](image3.png) | –7.7 | ARG 252, GLY 403, ARG 421, THR 11, ARG 398, THR 6, GLN 404, GLY 334, SER 3 | PRO 332, PRO 405, PHE 335, ASP 402, GLN 8 | –6.7 | ASN 58, ARG 17, ASP 59, ASN 61, ASP 381, ASP 379, LYS 436, PRO 433 | VAL 383, TRP 434, MET 435, ASP 378, |
2.3.2. ADMET Analysis

The most promising docked compounds were further investigated by the SwissADME online tool, which provides information on pharmacokinetics, drug-likeness, and physicochemical properties. According to Lipinski’s rule, all compounds violated the rule of lipophilicity while Olean-12-en-3-ol, acetate, (3beta)- and Stigmasterol violated the rule of molar refractivity. When a drug fails to meet two or more criteria, it is classified as a non-orally available drug. However, all of the compounds had one violation, indicating that they are orally available or bioavailable drugs. According to Lipinski’s criteria, all of the compounds exhibited orally active likeness characteristics. All of the compounds had no Blood-brain barrier penetration and lowered GI absorption. However, this study does not determine whether a compound has a specific biological effect. Table 9 presents the properties of the best seven best-docked compounds, such as molecular weight, no. of hydrogen bond acceptor and donor, no. of rotateable bond, Lipinski rule, and lipophilicity, while Figure 7 presents the bioavailability radar of best-docked compounds. Table S1 tabulates the pharmacokinetic properties of best-docked compounds. Olean-12-en-3-ol, acetate, (3beta)-, and 11-Oxours-12-en-3-yl acetate were predicted to have carcinogenic and immunotoxic properties in ProTox-II. In this investigation, all compounds were predicted to have minimal toxicity, except beta-Amyrin, which was predicted to be non-toxic. Table S2 presents different compounds along with their predicted toxicity class and LD50 value.

Table 9. Lipinski rule of five and solubility of best-docked compounds.

| Sr no. | Best-Docked Compounds          | Lipinski’s Rule | Solubility               |
|--------|--------------------------------|-----------------|--------------------------|
|        |                                | HBD  | HBA  | MWT     | Lipophilicity | M.R  | LR | ESOL Class | Ali Class | Silicos-IT Class |
| 1      | Urs-a(11),12-dien-3-ol         | 1    | 1    | 424.7  | 4.81       | 134.67| 1  | PS          | PS         | PS             |
| 2      | Olean-12-en-3-ol, acetate, (3beta)- | 0    | 2    | 468.75 | 5.19       | 144.62| 1  | PS          | IS         | PS             |
| 3      | beta-Amyrin                    | 1    | 1    | 426.72 | 4.74       | 134.88| 1  | PS          | PS         | PS             |
| 4      | 11-Oxours-12-en-3-yl acetate   | 0    | 3    | 482.74 | 4.79       | 145.08| 1  | PS          | PS         | PS             |
| 5      | Campesterol                    | 1    | 1    | 400.68 | 4.92       | 131.23| 1  | PS          | PS         | MS             |
| 6      | beta-Sitosterol                | 1    | 1    | 414.71 | 4.79       | 133.23| 1  | PS          | PS         | PS             |
| 7      | Stigmasterol                   | 1    | 1    | 412.69 | 5.01       | 132.75| 1  | PS          | PS         | MS             |

HBD; hydrogen bond doners, HBA; hydrogen bond acceptors, MWT; molecular weight, M.R; molar refractivity, LR; Lipinski rule, PS; poorly soluble, MS; moderate soluble, and IS; insoluble.
Figure 7. The bioavailability radar of best-docked compounds. The pink area represents oral bioavailability, considering factors such as polarity, lipophilicity, saturation, size, flexibility, and solubility.

3. Discussion

The phytochemicals profiling showed that the extract of *F. vasta* is a good source of carbohydrates, alkaloids, steroids, glycosides, flavonoids, phenols, tannins, and saponins. The antioxidant, antimicrobial, antifungal, antidiabetic, anti-inflammatory, anti-cancer, and antihypertensive effects are known to exist in these recognized phytochemical classes [58].
Some classes such as alkaloids have anti-viral, antifungal, antitumor, and antimicrobial activity [59]; flavonoids, phenols, and tannins have antioxidant and anti-cancer potential [60]; and saponins have antidiabetic, antibacterial, anti-inflammatory, and anti-cancer properties [61]. These phytochemicals in F. vasta extract may play a part in its therapeutic benefits. Ficus genus is medically important due to the presence of high value of total bioactive contents (TPC and TFC) [62]. Previously, some flavonoid compounds were identified in leaves of F. vasta [25]. The high value of total phenolic and flavonoid contents in plant extract correlates with the strong antioxidant activities [63].

To perform in-depth phytochemical identification, the ethanolic extract was evaluated by gas chromatography-mass spectrometry. The GCMS chromatogram of F. vasta ethanolic extract showed 28 peaks of compounds. Major compounds of GCMS consisting of Stigmasterol, 22,23-dihydro, 11-Oxours-12-en-3-yl acetate, Phytol, n-Hexadecanoic acid, Quinic acid, 11 14 17-eicosatrienoic acid methyl ester, 4-((1E)-3-Hydroxy-1-propenyl)-2-methoxyphenol, and 2,3-Dihydrobenzofuran. In GCMS, most of the compounds related to the classes like fatty acids, steroids, vitamins, and esters. The compounds identified by GCMS were reported to possess different biological activities. On this basis, we decided to examine antioxidant, antibacterial, antifungal, anti-viral, cytotoxicity, and antidiabetic activities.

According to the literature, the antioxidant activity of the ethanolic extract in aerial parts of F. vasta has not been reported, while the methanol extract of F. vasta leaves showed the antioxidant activity [25]. The results of the DPPH, ABTS, FRAP, and CUPRAC activities showed that there is a direct link of antioxidant activities and the polyphenol contents (i.e., high value of phenolic and flavonoid contents correlates with the strong antioxidant activity) [63].

The β-amylase initiates carbohydrate digestion by hydrolyzing 1,4-glycosidic bonds in polysaccharides to disaccharides, which is followed by β-glucosidase catalyzing the disaccharides to monosaccharides, resulting in postprandial hyperglycemia [64,65]. As a result, β-amylase and β-glucosidase inhibitors can control hyperglycemia by delaying carbohydrate digestion and lowering postprandial plasma glucose levels [66]. There is no data in the literature about the in vitro antidiabetic studies of F. vasta. Our results showed that ethanolic extract of Ficus vasta exhibits excellent β-glucosidase and β-amylase inhibitory effects. Such significant inhibition of β-amylase and β-glucosidase may be due to the presence of some phytocompounds which were identified by GCMS profiling, such as Ursa-9(11),12-dien-3-ol and beta-Amyrin which showed significant binding affinities with these enzymes, and due to presence of some other compounds in the extract. This suggests the potential of F. vasta for the management of diabeties.

The antibacterial ability of F. vasta was tested against five gram-positive strains and two gram-negative strains. Most of the bacteria employed in the assay showed a significant zone of inhibition (>9 mm) in the results. The antifungal ability of F. vasta was tested against three strains, including Aspergillus niger, Fusarium avenaceum, and Fusarium brachygibbosum. Most of the fungi employed in the test showed a significant zone of inhibition in the results. The anti-viral potential against three strains (i.e., avian infectious bronchitis virus (IBV), Influenza virus (H9), and Newcastle disease virus (NDV)) was carried out using a haemagglutination test method. The ethanolic extract of F. vasta was effective and strongly active against the viral strains. The presence of phytochemical components such as alkaloids, phenolic and flavonoid compounds could be responsible for the antimicrobial activities [67]. Tentative identification of the ethanolic extract by GCMS revealed many compounds with antibacterial, antifungal, and antiviral activities, namely Methyl (Z)-5,11,14,17-eicosatetraenoate [4,8], Octadecanoic acid [45], 4-((1E)-3-Hydroxy-1-propenyl)-2-methoxyphenol [34], Nonanoic acid [31], Catechol [27], and Stigmasterol, 22,23-dihydro [54] etc. Methanolic extract obtained from leaves of F. vasta previously tested against E. coli, Pseudomonas aeruginosa, Streptococcus pneumonia, Salmonella typhimurium, and Staphylococcus epidermidis [25,68].
To the best of our knowledge, there is no information in the literature about the ethanolic extract of *F. vasta* thrombolytic activity. Plants containing flavonoids and polyphenols have been reported to possess thrombolytic activity and hence attracted researchers to explore more for better and safer drugs of plant origin [69]. The thrombolytic activity of *F. vasta* was significant. Microbial plasminogen activators such as staphylokinase and streptokinase function as co-factoring molecules to promote development [70].

Hemolysis is the breakdown or disruption of the integrity of the RBC membrane, which causes hemoglobin to be released from red blood cells [71]. Some traditional plants sometimes become harmful if used over an extended period. There are chemical elements in many plants that may have an anti-hemolytic or hemolytic effect on human erythrocytes. Plant extracts can disrupt red blood cell membranes, leading to serious side effects such as hemolytic anemia [72]. Therefore, it is important to evaluate the possible hemolytic activity of a number of the frequently used herbs. When there is more than 30% hemolysis, the plant extracts are thought to be harmful to erythrocytes [73]. Table 7 displays the hemolytic activity of aerial parts of the entire *F. vasta* plant. Plant hemolysis was measured as a percentage of hemolysis. The results showed that extract had the hemolytic activity (6.39 ± 0.45%). Since the hemolysis activity of extract is less than 30%, they are all nontoxic and safe for human utilization. This is the first time that the *F. vasta* plant’s hemolytic activity has been reported.

MTT activity was used to evaluate the effect of *F. vasta* extract on HepG2 cell growth. Treatment with *F. vasta* extract for 48 h inhibited the growth of cells in a dose-dependent manner. Our results found that *F. vasta* is rich in antioxidants which can act as scavengers for free radicals created by the body’s cells as a result of a variety of metabolic reactions and external influences. These antioxidants are useful to cells since they help to prevent the growth of cancer [12].

In recent years, computer-based modeling techniques have been increasingly used to predict the interactions between small molecules and their biological targets. This approach can provide useful insights into the molecular basis of the biological activity of natural products and the possible mechanisms of action and binding modes of active compounds [74]. To understand the ability of the compounds to inhibit enzymes and to find a correlation between the in vitro enzyme inhibition results, all compounds from the GCMS analysis of ethanolic extract were docked against α-amylase and α-glucosidase enzymes, along with acarbose. According to the validation criteria, RMSD values less than 2.0 Å demonstrate that the docking protocol is capable of accurately predicting the co-crystallized ligand’s binding orientation [75]. The hydrogen bond and other hydrophobic interactions, such as alkyl and pi-alkyl, plays an important protein-ligand interactions as well as ensuring the stable binding of ligands with proteins [76].

For further investigation, the best docked compounds were studied using online tool SwissADME which gave information about their pharmacokinetics, drug likeness, and physiochemical properties [77]. According to Lipinski, a chemical can exhibit drug-like behaviour if it meets all of the following criteria: (i) Molecular weight (<500); (ii) Hydrogen bond donor (≤5); (iii) hydrogen bond acceptor (less than and equal to 10); (iv) Lipophilicity (Log Po/w, <5); and (v) molar refractivity 40 to 130. Those compounds which followed the Lipinski rule were considered potential therapeutic candidates [78]. When a drug fails to meet two or more of Lipinski’s criteria, it is classified as non-orally available drug. However, all of the compounds had 1 violation, indicating that they are bioavailable or orally available drugs. According to Lipinski’s criteria, all of the best docked compounds exhibited orally active likeness characteristics. Compounds with lower lipophilicity, molecular weight, and hydrogen bond capacity are said to have good absorption, high permeability, and bioavailability [79,80]. All of the compounds had no blood-brain barrier penetration and low GI absorption. However, this study does not determine whether a compound has a specific biological effect. The colors in the bioavailability radar of best docked compounds represent the best physico-chemical space indicator for oral bioavailability, taking into account factors such as lipophilicity, saturation, size, flexibility, polarity, and solubility.
LogP is a measure of lipophilicity, can range from \(-0.7\) to \(+5.0\), molecular weight can range from 150 to 500 (g/mol). The TPSA, which is a measure of the size and polarity of a molecule, ranges from 20 to 130 Å². The logS (ESOL) insolubility, which measures the solubility of a molecule, ranges from 0 to 6. The number of rotatable bonds for a molecule is between 0 to 9, with an unsaturation fraction between 0.25 and 1.0. This indicates that the carbon atom fraction in sp³ hybridization cannot be less than 0.25 [81]. ProTox-II is a program that predicts toxicity based on the similarity of chemical structures and then compares them to other chemicals with known toxicities [82]. In silico toxicity analysis of seven phytocompounds showed that they all have low toxicity potential. However, beta-Amyrin was predicted to be non-toxic.

Overall, Ursa-9(11),12-dien-3-ol, Olean-12-en-3-ol, acetate, (3beta)-, beta-Amyrin, 11-Oxours-12-en-3-yl acetate, Campesterol, beta-Sitosterol, and Stigmasterol may have some potentials as inhibitors of important proteins (\(\alpha\)-glucosidase and \(\alpha\)-amylase) and might have contributed either singly or in synergy to the antidiabetic properties of \(F.\) vasta. However, further research is needed to explore the pharmacokinetic properties of these compounds and whether or not they are effective in both in vitro and in vivo models.

4. Materials and Methods

4.1. Materials and Reagents

Chemicals used in the study were of analytical grade purchased from Sigma Aldrich, Louis, MO 63103, USA. All of the standards were also purchased from Sigma.

4.2. Collection and Extraction of Plant

The aerial parts of \(F.\) vasta were collected in September 2020 from Jazan province, Fayfa Mountains, Saudi Arabia. A botanist identified the plant at the Science College, King Saud University, Saudi Arabia. A Voucher specimen No. 24557 was submitted to the herbarium of the Science College, King Saud University. The plant was air-dried and then subjected to crushing and grinding to form a coarse powder. Air-dried plant was macerated with 80% ethanol for 15 days. After maceration, it was filtered and then concentrated (40 °C) using a rotary evaporator (Heidolph, Germany), yielding a dark brown residue and further air dried to yield 98.5 g extract.

4.3. Phytochemical Analysis

4.3.1. Preliminary Phytochemical Profiling

The presence of secondary and primary metabolites such as alkaloids, steroids, terpenoids, resins, carbohydrates, amino acids, phenols, lipids, proteins, saponins, glycosides, tannins, and flavonoids was determined by qualitative phytochemical analysis of \(F.\) vasta extract [83].

4.3.2. Total bioactive contents (TPC and TFC)

**TPC**

The Folin-Ciocalteu method was used to determine the total phenolic content (TPC) as previously reported in the literature [84]. Different concentrations of Gallic acid (0.05-0.5 mg/mL) were used as a standard to establish a standard calibration curve (Figure S1). The sample solution was prepared as 0.5 mg/mL, from which an aliquot of 0.1 mL was taken in a test tube, followed by adding Folin-Ciocalteu’s reagent (0.1 mL). Then, 10% Na₂CO₃ (2.8 mL) was combined with the resultant solution, and the solution was placed for 30 min in the dark. Absorbance was read at 765 nm using a BioTek Synergy HT microplate reader. TPC was expressed in milligrams of Gallic acid equivalent per gram of dry extract.

**TFC**

The aluminum chloride colorimetric method was used to estimate the content of flavonoids [84]. In 96% ethanol, standard quercetin solutions of 30, 40, 50, 60, 70, 80, 90, 100 µg/mL were prepared (Figure S2). Firstly, the 1 mg/mL solution of extract and then
50 µL extract and standard solutions were added in 10 µL of aluminium chloride (10%) solution, and then 150 µL of ethanol (96%) was added. At last, in 96 well plates, 10 µL of sodium acetate (1M) was added to the mixture. Ethanol was used as a blank, and then all reagents were mixed, and the mixture was then incubated for 40 min at room temperature in the dark. Finally, the absorbance was measured at 415 nm using a BioTek Synergy HT microplate reader. TFC was expressed in milligrams of quercetin equivalents per gram of dry extract.

4.3.3. Gas Chromatography-Mass Spectroscopy Analysis

The phytometabolites of ethanolic extract of *F. vasta* were determined by GCMS analysis using Agilent, 6890 series, and Hewlett Packard, 5973 mass selective detector. An HP-5MS column with a length of 30m, a diameter of 250 µL, and a film thickness of 0.25 µL were used to achieve the best possible separation. The volume of 1.0 µL of the extract was diluted with the appropriate solvent and injected at 250 °C in a splitless mode. Helium gas as a carrier was used at a constant flow rate of 1.02 mL/min., the temperature was increased gradually, starting at 50–150 °C and increasing by 3 °C per min, with a 10 min holding time at each temperature. The final temperature was set to 300 °C at 10 °C/min.

The components were identified using their retention indices, and the mass spectrum was interpreted using the National Institute of Standards and Technology database (NIST) [85].

4.4. Biological Activities

4.4.1. Antioxidant Activities

The antioxidant activities of *F. vasta* included determining the free radical scavenging and reducing power activities. Ascorbic acid was used as a standard for all antioxidant activities. The DPPH, ABTS, FRAP, and CUPRAC activities were performed according to the literature with minor modifications [86].

**DPPH Assay**

A solution of 0.1 mM DPPH was prepared, and 90 µL of DPPH solution was added to a 96-well plate, followed by 10 µL of the substance being tested. The mixture is then incubated for 30 min, after which the absorbance is read at 517 nm using a BioTek Synergy HT microplate reader.

**ABTS Assay**

ABTS activity was carried out by the modified method in which 100 µL of sample solution was mixed with 200 µL of prepared ABTS solution. This mixture was incubated for 30 min at room temperature. The absorbance was recorded at 417 nm using a BioTek Synergy HT microplate reader.

**FRAP Assay**

For this activity, 100 µL of *F. vasta* extract (1mg/mL) was mixed with 2 mL of FRAP reagent and mixture was incubated for 30 min. The absorbance was measured at 593 nm using a BioTek Synergy HT microplate reader. Similarly, the blank sample was prepared without extract.

**CUPRAC Assay**

For this activity, 100 µL solution of *F. vasta* extract was prepared, and added into 7.5 mM (200 µL) neocuprline, 10 mM (200 µL) CuCl₂, and 1M (200 µL) ammonium acetate buffer (pH 7.5) reaction mixture. This mixture was incubated for 30 min then absorbance was recorded at 450 nm using a BioTek Synergy HT microplate reader.
4.4.2. Enzyme Inhibition Activities
α-Glucosidase Inhibition Assay

The method described in previous literature was followed to determine the α-glucosidase inhibitory activity [87]. In this assay acarbose was used as a standard or positive control and methanol as a negative control. The volume of 10 µL of a plant extract, 70 µL of a 0.1 molar phosphate buffer (pH 6.8), and 10 µL of α-glucosidase was added to the wells of a 96 well plate and incubated for 15 min at 30 °C. In the end, 10 µL p-Nitrophenyl-α-D-glucopyranoside solution was added for the next 30 min and absorbance was read at 405 nm using a BioTek Synergy HT microplate reader.

α-Amylase Inhibition Assay

According to the previously reported method [88], the starch iodine test method was used to evaluate the inhibitory activity of α-amylase. 25 µL of 0.02 molar sodium phosphate buffer containing 6 millimolar NaCl, 20 µL of soluble starch (concentration 1% w/v), and 20 µL of plant extract/acarbose was incubated at 37 °C for 5 min. Acarbose was used as a standard. Then 15 µL of amylase solution were placed into each well and incubated at 37 °C for the next 10 min. After that, 20 µL of 1 molar was added to stop the reaction. Then, 100 µL of iodine reagent was added. The color change was observed, and absorbance was measured at 620 nm using a BioTek Synergy HT microplate reader. The color of the mixture changes based on the presence of starch. If there is an active inhibitor, the color will be dark blue. If there is no inhibitor, the color will be yellow. If the starch is partially degraded, the color will be brownish, indicating that the inhibitor is partially active.

4.4.3. Antibacterial Activity

Strains of Bacteria

Antibacterial activity was performed against the five positive strains, including Bacillus subtilis, Bacillus pumilus, Staphylococcus epidermidis, Staphylococcus aureus, Micrococcus luteus, and two negative strains, including Escherichia coli, and Bordetella bronchiseptica. These bacterial strains were provided by the Microbiology lab of the Islamia University of Bahawalpur.

Agar Well Diffusion

The culture of bacteria was streaked on Mueller Hinton agar plates and placed in an incubator for 24 h at 37 °C. After 24 h, the colony was picked and inoculated into the saline solution and vortexed. In the end, turbidity was set to 0.5 McFarland standards. The plant extracts were prepared in DMSO at four concentrations 25, 50, 75, and 100 mg/mL. Mueller Hinton agar plates were inoculated with various strains of bacteria. The organisms were spread evenly over the surface of the agar, and four wells (6 mm in diameter) were punched into each plate. 100 µL of sample solution was added to each well, and the plates were incubated at 37 °C for 24 h. The diameter millimeter of a zone of inhibition was measured and ceftriaxone was used as standard in the activity [89].

4.4.4. Antifungal Activity

Fungal Strains

Antifungal activity was performed against the three strains, including Aspergillus niger, Fusarium avenaceum, and Fusarium brachygibbosum. These fungal strains were provided by the Microbiology lab of the Islamia University of Bahawalpur.

Agar Tube Dilution

Antifungal activity was performed according to the previous method with little modifications [90]. The sample solutions were prepared in DMSO at 20 and 40 mg/mL concentrations. Agar was prepared, and the sample solution was added to melted agar. Then tubes were solidified at room temperature in a slanting position. After solidification, each slant was inoculated by 4 mm diameter piece of fungal strain. Terbinafine was used as
standard and DMSO as the negative control in the activity. Tubes were incubated for 3 days at 27–29 °C. The percentage inhibition was measured with the following formula:

\[
\text{Percentage inhibition} = \frac{\text{Linear growth in test tubes (mm)}}{\text{Linear growth in control (mm)}} \times 100
\]  

4.4.5. Anti-viral Activity

Viral Strains

Anti-viral activity was performed against the three strains including Avian Infectious Bronchitis Virus (IBV, H120 strain from IZO S.U.R.L 99/A-25124), Newcastle disease virus (NDV, Lasota strain), and Influenza virus (H9. H9N2 strain) from Brescia, Italy.

Inoculation of Viruses in Chicken Embryonated Eggs

The reported procedure was performed for anti-viral activity in ethanolic extract of *F. vasta* [91]. Chicken eggs are used for preliminary growth of the viruses and formation of novel vaccines. Eggs are considered as one of the most used media due to excellent growth of viruses. The chicken eggs are easy to collect, easy to handle, aseptic conditions, cheap, and require little space for storage making them the best resource of viral inoculations studies. The viruses accumulate in the chorioallantoic membrane fluid during incubation period of the eggs and keep replicating. Viral strains were cultured in the 7 to 11 days old embryonated poultry eggs. Pathogen-free eggs were collected from Government Poultry Farm, Model Town a, Bahawalpur. Ethyl alcohol was used to sterilize the eggs, and a sterile needle was used to make holes in the egg. Viral strains were injected through the chorioallantoic route into the embryonated eggs with the help of a syringe (5 cc). After inoculation, the hole was closed with melted wax after the inoculation. The eggs were incubated at 37 °C for 48–72 h. Melted wax was then used to close the hole. The incubation period for the inoculated eggs was 48 to 72 h at 37 °C. Titer viruses were then assessed after collecting the allantoic fluid with the syringe in the Eppendorf at 4 °C for further processing. A 96-well microtiters round bottom plate was used for performing the Haemagglutination test.

Haemagglutination (HA) Test

The first step of the Haemagglutination test is to prepare 1% red blood cells (R.B.Cs.) Alsever solution was poured into a test tube, and fresh chicken blood (5 mL) was added. Blood (5 mL) was centrifuged for 5 min at 4000 rpm, and the supernatant was removed. For better results and more purification, the process was repeated three times. In the Eppendorf tubes, 10 µL packed R.B.Cs were mixed with 1 mL phosphate buffered saline solution at pH 7.4 to prepare a 1% R.B.Cs solution. To avoid precipitation, Eppendorf tubes were shaken gently. In each microtiter plate well, PBS (50 µL) was added. The samples (50 µL) were added in the first column. The diluted upto the 11th and 12th well was left as negative control only containing PBS. After that, 1% RBCs solution (50 µL) was added to all 12 wells, and the plate was incubated for 2 to 3 h at 37 °C. The uniform red color indicated positive results; however, red dots at the bottom of the well indicate negative results. 56 Haemagglutination Titer had the highest dilution number showing positive results. The test was used for testing the titer of Avian Infectious Bronchitis Virus (IBV), Newcastle disease virus (NDV), and Influenza virus (H9).

4.4.6. Thrombolytic Activity

The blood samples were taken in the incubated Eppendorf tubes for 45 min at 37 °C. Serum was removed from the blood sample without damaging the blood clot, and the Eppendorf tube was weighed again. In each pre-weighed Eppendorf tube with a blood clot, 1 mg/mL (100 µL) of plant extract was added. Streptokinase was used as a standard and negative non-thrombolytic control. Eppendorf tubes containing blood samples and plant fractions were incubated at 37 °C for 90 min. After 90 min, the thrombolytic activity was observed in these Eppendorf tubes. The fluid released in the Eppendorf tubes was removed.
and weighed again. The weight difference of Eppendorf tubes showed the antithrombotic activity of the extract or fractions against streptokinase [92]:

\[
\text{Percentage of clot lysis} = \left( \frac{W_r}{W_c} \right) \times 100
\]  

(2)

where: \( W_r \) = released clot weight; \( W_c \) = clot weight

4.4.7. Hemolytic Activity

The hemolytic activity was performed according to the literature with some modifications [93]. A hemolytic activity on human erythrocytes was used to determine the preliminary toxicity of phytochemical compounds from plant extract. To prepare the erythrocyte suspension, blood (type O blood from Civil Hospital, Bahawalpur) was used. The volume of 50 \( \mu \)L of the erythrocyte suspension (pH 7.4) and 100 \( \mu \)L of the extract were mixed and incubated for 1 h at 37 °C. After that, 850 \( \mu \)L of phosphate-buffered saline (pH 7.4) was added in already prepared mixture, then centrifuged for 3 min at 3000 rpm. The supernatant was obtained, and the absorbance at 540 nm of the hemolysis was measured by using a BioTek Synergy HT microplate reader. A total of 0.1% Triton X-100 was used as a positive control while phosphate-buffered saline was used as a negative control:

\[
\text{Hemolysis percentage} = \frac{\text{Absorbance of sample} - \text{Absorbance of negative control}}{\text{Absorbance of positive control}} \times 100
\]  

(3)

4.4.8. Cytotoxicity

The human HepG2 liver cancer cells were grown in the Dulbecco’s Modified Eagle’s Medium (DMEM), with added 10% fetal bovine serum (FBS), 100 IU/mL penicillin, and 100 \( \mu \)g/mL streptomycin in a 75 cm\(^2\) flask and maintained at 37 °C with 5% CO\(_2\) incubator. Cells were treated with extracts dissolved in DMSO (0.05% concentration).

Determination of Cell Viability

Cell viability was determined by MTT activity as described in the literature with some modifications [94]. Firstly, HepG2 cells were treated with different concentrations from 10 to 100 \( \mu \)g/mL of extracts for 48 h. Following treatment, each well was introduced with a 10 \( \mu \)L MTT reagent and further incubated for 4 h. Then 150 \( \mu \)L of DMSO was subsequently introduced to dissolve formazan crystals, and absorbance was read at 490 nm. The % age of cell viability was calculated:

\[
\text{Cell viability %} = \frac{\text{Absorbance of sample} - \text{Absorbance of blank}}{\text{Absorbance of control} - \text{Absorbance of blank}} \times 100
\]  

(4)

4.5. In Silico Activities

4.5.1. Molecular Dockings

The interaction between the bioactive compounds discovered in \( F. \) \( vasta \) ethanolic extract, \( \alpha\)-glucosidase (PDB: 5zcb), and \( \alpha\)-amylase (PDB: 4w93) was assessed using PyRx software. The 3D shapes of proteins were taken from the RCSB Protein Data Bank (https://www.rcsb.org/ accessed on 30 May 2022). First, the proteins were prepared for docking using the Discovery studio by removing water and ligands, inserting polar hydrogen atoms, and saving them in PDB format. Then download the ligand in SDF format from PubChem (https://pubchem.ncbi.nlm.nih.gov accessed on 30 May 2022). The Open Babel software converted the ligands to PDB files. The prepared and optimized ligands were docked blindly in the protein’s grid box to allow them to find any suitable binding location [95]. The docking studies were validated by superimposing the co-crystallized ligand (Acarbose) with extracted Acarbose from crystal structure and redocked to \( \alpha\)-amylase and \( \alpha\)-glucosidase crystal structures. The Ligplot software was used to visualize 2D structures of ligand-protein interactions [96].
4.5.2. ADMET Analysis

The ADME characteristics of the best docked bioactive compounds were assessed using the online SwissADME (http://www.swissadme.ch/ accessed on 12 June 2022) [77]. The best-docked compound’s toxicity was checked using the online tool PROTOX II (https://tox-new.charite.de/, accessed on 12 June 2022) [82].

4.6. Statistical Analysis

The findings were all presented as mean standard deviation (mean ± SD). The information obtained through quantitative analysis IBMSPSS (v20, Chicago, IL, USA) was used to perform a one-way analysis of variance (ANOVA) followed by post-hoc test on the phytochemicals. Significant values were defined as p values less than 0.05.

5. Conclusions

The results of the present study suggest that ethanolic extract of *Ficus vasta* Forrsk. has identified bioactive phytochemicals responsible for therapeutic and pharmacological activities. *F. vasta* showed the good TPC, TFC, and antioxidant potential and had a good antidiabetic potential for α-amylase and α-glucosidase inhibition. The extract exhibited the good antibacterial, antifungal, and anti-viral potentials against the strains. *F. vasta* extract inhibited the growth of HepG2 cells in a dose-dependent manner. The GCMS analysis of ethanol extract indicated the tentative presence of important phytocompounds, which justified their biological activities. Hence, it is concluded that in vitro analysis of *F. vasta* showed the plant’s medicinal potential with respect to antioxidant, antidiabetic, thrombolytic, enzyme inhibition, cytotoxicity, anti-viral, antifungal, and antibacterial potential. The in silico molecular docking studies further explained the enzyme inhibition activity. Based on in vitro and in silico docking studies, further investigation is required to evaluate its toxicity profile and clinical studies. Conclusively, the findings of this research could help researchers who are struggling continuously for the development of novel and effective drugs from natural products. The observed phytochemical and biological potential of this plant indicated that it might be valuable for further isolation of bioactive compounds.

**Supplementary Materials:** The following are available online at https://www.mdpi.com/article/10.3390/antibiotics11091155/s1, Figure S1: Standard curve, regression equation and R2 for quantification of phenolics, Figure S2: Standard curve, regression equation and R2 for quantification of flavonoids, Figure S3: Antibacterial results of *F. vasta* ethanolic extract, Figure S4: Graphical representation of best three docked compounds and Acarbose against α-glucosidase and α-amylase, Figure S5. Superimposition of re-docked (Red) onto co-crystallized Acarbose (Yellow) in the active site. "A" α-amylase (RMSD value = 1.525 Å) and "B" α-glucosidase (RMSD value = 1.234 Å), Table S1: Pharmacokinetic properties of best-docked compounds, Table S2: Toxicity profiles of best-docked compounds.

**Author Contributions:** Conceptualization, H.Y.A. and J.A.-Q.; methodology, K.-u.-R.K. and S.A.; software, M.A.; validation, B.A.G. and F.U.; formal analysis, J.H.S.; investigation, H.M.A., S.A. and A.A.-T.; resources, H.Y.A.; data curation, A.A.; writing—original draft preparation, H.Y.A. and S.A.; writing—review and editing, J.A.-Q., A.A.-T. and K.-u.-R.K.; visualization, B.A.G.; supervision, H.Y.A. and K.-u.-R.K.; project administration, A.A.-T.; funding acquisition, H.Y.A. All authors have read and agreed to the published version of the manuscript.

**Funding:** The authors are grateful to the King Saud University, Riyadh, Saudi Arabia for funding this study through Researchers Supporting Project number RSP2022R504.

**Institutional Review Board Statement:** All of the experiments were carried out in accordance with the NIH guidelines and were approved by the Department of Pharmaceutical chemistry’s concerned committee (1050/AS & RB/12/11/2021).

**Informed Consent Statement:** Informed Consent was obtained from all objects involved in the studies.

**Data Availability Statement:** Not applicable.
Acknowledgments: The authors are thankful to Researchers Supporting Project number (RSP2022R504), King Saud University, Riyadh, Saudi Arabia.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Ghalloo, B.A.; Khan, K.-U.-R.; Ahmad, S.; Aati, H.Y.; Al-Qahtani, J.I.; Ali, B.; Mukhtar, I.; Hussain, M.; Shahzad, M.N.; Ahmed, I. Phytochemical Profiling, in Vitro Biological Activities, and In Silico Molecular Docking Studies of Dracaena reflexa. *Molecules* 2022, 27, 913. [CrossRef]
2. Egamberdieva, D.; Wirth, S.; Behrendt, U.; Ahmad, P.; Berg, G. Antimicrobial Activity of Medicinal Plants Correlates with the Proportion of Antagonistic Endophytes. *Front. Microbiol.* 2017, 8, 199. [CrossRef]
3. Aumeeruddy, M.; Mahmoonodally, F. Combating breast cancer using combination therapy with 3 phytochemicals: Piperine, sulforaphane, and thymoquine: Combination therapy with phytochemicals. *Cancer* 2019, 125, 1600–1611. [CrossRef]
4. Ahn, K. The worldwide trend of using botanical drugs and strategies for developing global drugs. *BMB Rep.* 2017, 50, 111. [CrossRef]
5. Kumar, S.; Kumar, V.; Prakash, O. Enzymes inhibition and antidiabetic effect of isolated constituents from Dillenia indica. *Biomed. Res. Int.* 2013, 2013, 382063. [CrossRef]
6. Salehi, B.; Ata, A.; Anil Kumar, N.V.; Sharopov, F.; Ramírez-Alarcón, K.; Ruiz-Ortega, A.; Abdulkhadja Ayatollahi, S.; Tsouh Fokou, P.V.; Kobarfard, F.; Amiruddin Zakaria, Z.; et al. Antidiabetic Potential of Medicinal Plants and Their Active Components. *Biomolecules* 2019, 9, 551. [CrossRef]
7. Okechukwu, P.; Sharma, M.; Tan, W.; Hor Kuan, C.; Chirara, K.; Gaurav, A.; Al-Nema, M. In-vitro anti-diabetic activity and in-silico studies of binding energies of palmatine with alpha-amylase, alpha-glucosidase and DPP-IV enzymes. *Pharmacia* 2020, 67, 363–371. [CrossRef]
8. Derosa, G.; Maffioli, P. α-Glucosidase inhibitors and their use in clinical practice. *Arch. Med. Sci. AMS* 2012, 8, 899–906. [CrossRef]
9. Erugur, N.; Kocyigit, U.M.; Taslimi, P.; Atas, M.; Tekin, M.; Gulcin, I. Screening the in vitro antioxidant, antimicrobial, anticholinesterase, antidiabetic activities of endemic Achillea cucullata (Asteraceae) ethanol extract. *S. Afr. J. Bot.* 2019, 120, 141–145. [CrossRef]
10. Park, J.W.; Chen, M.; Roberts, L.R.; Schwartz, M.; Chen, P.J.; Kudo, M.; Johnson, P.; Wagner, S.; Orsini, L.S. Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study. *Liver Int.* 2015, 35, 2155–2166. [CrossRef]
11. Machana, K.; Weerapreeayakul, N.; Barusrux, S. Anticancer effect of the extracts from Polyalthia eventa against human hepatoma cell line (HepG2). *Asian Pac. J. Trop. Biomed.* 2012, 2, 368–374. [CrossRef]
12. Venkatachalapathy, D.; Shivamallu, C.; Prasad, S.K.; Thangaraj Saradha, G.; Rudrapathy, P.; Amachawadi, A.; Patil, S.S.; Syed, A.; Elgorban, A.M.; Bahkali, A.H.; et al. Assessment of Chemopreventive Potential of the Plant Extracts against Liver Cancer Using HepG2 Cell Line. *Molecules* 2021, 26, 4595. [CrossRef]
13. Chaudhry, G.-e.-S.; Sohimi, N.; Mohamad, H.; Zafar, M.; Ahmed, A.; Yeong, Y.S.; Tengku Muhammad, T.S. Xylocarpus moluccensis Induces Cytotoxicity in Human Hepatocellular Carcinoma HepG2 Cell Line via Activation of the Extrinsic Pathway. *Asian Pac. J. Cancer Prev.* 2021, 22, 17–24. [CrossRef]
14. Joshi, B.; Panda, S.K.; Jouneghani, R.S.; Liu, M.; Parajuli, N.; Leyssen, P.; Neyts, J.; Luyten, W. Antibacterial, Antifungal, Antiviral, and Anthelmintic Activities of Medicinal Plants of Nepal Selected Based on Ethnobotanical Evidence. *Evid. Based Complement. Altern. Med.* 2020, 2020, 1043471. [CrossRef]
15. Khan, S.U.; Anjum, S.I.; Ansari, M.J.; Khan, M.H.U.; Kamal, S.; Rahman, K.; Shoaiib, M.; Man, S.; Khan, A.J.; Khan, S.U.; et al. Antimicrobial potentials of medicinal plant’s extract and their derived silver nanoparticles: A focus on honey bee pathogen. *Saudi. J. Biol. Sci.* 2019, 26, 1815–1834. [CrossRef]
16. Spengler, G.; Gaidacs, M.; Donadu, M.G.; Usai, M.; Marchetti, M.; Ferrari, M.; Mazzarello, V.; Zanetti, S.; Nagy, F.; Kovacs, R. Evaluation of the antimicrobial and antiviral potential of essential oils isolated from Juniperus oxycedrus L. spp. macrocarpa aerial parts. *Microorganisms* 2022, 10, 758. [CrossRef]
17. Tako, M.; Kerekes, E.B.; Zambrao, C.; Kotogán, A.; Papp, T.; Krisch, J.; Vágvölgyi, C. Plant Phenolics and Phenolic-Enriched Extracts as Antimicrobial Agents against Food-Contaminating Microorganisms. *Antioxidants* 2020, 9, 165. [CrossRef]
18. Simonetti, G.; Brusil, E.; Pasqua, G. Antifungal Activity of Phenolic and Polyphenolic Compounds from Different Matrices of Vitis vinifera L. against Human Pathogens. *Molecules* 2020, 25, 3748. [CrossRef]
19. Montenegro-Landivar, M.E.; Tapia-Quirós, P.; Vecino, X.; Reig, M.; Valderrama, C.; Granados, M.; Cortina, J.L.; Saurina, J. Polyphenols and their potential role to fight viral diseases: An overview. *Sci. Total Environ.* 2021, 801, 149719. [CrossRef]
20. Murugesu, S.; Selamat, J.; Perumal, V. Phytochemistry, Pharmacological Properties, and Recent Applications of Ficus benghalensis and Ficus religiosa. *Plants* 2021, 10, 2749. [CrossRef]
21. Raju, N.; Yesuf, E.; Bekele, M.; Wabe, N. Investigation of In Vitro Anthelmintic Activity of Ficus vasta leaves. *Asian J. Pharm. Biol. Res.* 2011, 1, 454–458.
22. Mosa, O.; Deng, J.; Burhan, S.; Elafith, M.; Mohamed, S. Evaluation of phytochemical and antimicrobial activities of some Sudanese medicinal plants. *J. Pharm. Pharm. Sci.* 2014, 3, 1769–1776.
23. Rashed, K.; Anthonissen, R.; Cappoen, D.; Verschaeye, L. Phytochemical Composition and Potential Genotoxic effects of Important Egyptian Medicinal Plants. *Pharmacog. Commun.* **2015**, *5*, 207–216. [CrossRef]

24. Rashed, K.; Ono, L. Evaluation of cytotoxicity, anti-herpes simplex virus type 1 (HSV-1) and antibacterial activities of Ficus vasta and phytoconstituents. *Int. Curr. Pharm. J.* **2013**, *3*, 211–218. [CrossRef]

25. Taviano, M.F.; Rashed, K.; Filocamo, A.; Cacciola, F.; Dugo, P.; Mondello, L.; Biscigno, C.; Acquaviva, R.; D’Arrigo, M.; Miceli, N. Phenolic profile and biological properties of the leaves of Ficus vasta Forssk. (*Moraceae*) growing in Egypt. *BMCM Complement. Altern. Med.* **2018**, *18*, 161. [CrossRef]

26. Tejero, I.; González-García, N.; González-Lafont, Á.; Lluch, J.M. Tunneling in green tea: Understanding the antioxidative activity of catechol-containing compounds. A variational transition-state theory study. *J. Am. Chem. Soc.* **2007**, *129*, 5846–5854. [CrossRef]

27. Kocaçalı¸skan, I.; Talan, I.; Terzi, I. Antimicrobial activity of catechol and pyrogallol as allelochemicals. *Z. Naturforsch. C.* **2006**, *61*, 639–642. [CrossRef]

28. de Castro Oliveira, L.G.; Brito, L.M.; de Moraes Alves, M.M.; Amorim, L.V.; Sobrinho-Júnior, E.P.C.; de Carvalho, C.E.S.; da Franca Rodrigues, K.A.; Arcanjo, D.D.R.; das Graças Lopes Cító, A.M.; de Amorim Carvalho, F.A. In vitro effects of the neolignan 2, 3-dihydrobenzofuran against Leishmania amazonensis. *Basic Clin. Pharmacol. Toxicol.* **2017**, *120*, 52–58. [CrossRef]

29. Moldovan, Z.; Marinca, O.; Povar, I.; Lupascu, T.; Longree, P.; Rota, J.S.; Singer, H.; Alder, A.C. Environmental exposure of anthropogenic micropollutants in the Prut River at the Romanian-Moldavian border: A snapshot in the lower Danube river basin. *Environ. Sci. Pollut. Res.* **2018**, *25*, 31040–31050. [CrossRef]

30. do Nascimento, M.A.; Vargas, J.P.C.; Rodrigues, J.G.A.; Leão, R.A.C.; de Moura, P.H.B.; Leal, I.C.R.; Bassut, J.; de Souza, R.O.M.A.; Wojcieszak, R.; Itabaiana, I. Lipase-catalyzed acylation of levoglucozan in continuous flow: Antibacterial and biosurfactant studies. *RSC Adv.* **2012**, *2*, 3027–3035. [CrossRef]

31. Sahin, N.; Kula, I.; Erdogan, Y. Investigation of antimicrobial activities of nonanoic acid derivatives. *Fresenius Environ. Bull.* **2006**, *15*, 141–143. [CrossRef]

32. Jang, Y.-W.; Jung, J.-Y.; Lee, I.-K.; Kang, S.-Y.; Yun, B.-S. Nonanoic acid, an antifungal compound from Hibiscus syriacus Ggoma. *Mycobiology* **2012**, *40*, 145–146. [CrossRef]

33. Kim, M.-M.; Kim, S.-K. Effect of phloroglucinol on oxidative stress and inflammation. *Food Chem. Toxicol.* **2010**, *48*, 2925–2933. [CrossRef]

34. Dandeekar, R.; Fegade, B.; Bhaskar, V. GC-MS analysis of phytoconstituents in alcohol extract of Epiphyllum oxypetalum leaves. *J. Pharmacogn. Phytochem.* **2015**, *4*, 149–154. [CrossRef]

35. Wang, G.-F.; Shi, L.-P.; Ren, Y.-D.; Liu, Q.-F.; Liu, H.-F.; Zhang, R.-J.; Li, Z.; Zhu, F.-H.; He, P.-L.; Tang, W.; et al. Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro. *Antivir. Res.* **2009**, *83*, 186–190. [CrossRef]

36. Duke, J.A. Chemicals in *Vitis vinifera* L. (*Vitaceae*). In *Dr. Duke’s Phytochemical and Ethnobotanical Databases*; Ag Data Commons: Washington, DC, USA, 2012.

37. Tyagi, T.; Agarwal, M. Phytochemical screening and GC-MS analysis of bioactive constituents in the ethanolic extract of *Pistia stratiotes* L. and *Eichhornia crassipes* (Mart.) solms. *J. Pharmacogn. Phytochem.* **2017**, *6*, 195–206. [CrossRef]

38. Ganesh, M.; Mohankumar, M. Extraction and identification of bioactive components in *Sida cordata* (Burm. f.) using gas chromatography–mass spectrometry. *J. Food Sci. Technol.* **2017**, *54*, 3082–3091. [CrossRef]

39. Islam, M.T.; Ali, E.S.; Uddin, S.J.; Shaw, S.; Islam, M.A.; Ahmed, M.I.; Chandra Shill, M.; Karmakar, U.K.; Yarla, N.S.; Khan, I.N.; et al. Phytol: A review of biomedical activities. *Food Chem. Toxicol.* **2018**, *121*, 82–94. [CrossRef]

40. Santos, C.C.d.M.P.; Salvadori, M.S.; Mota, V.G.; Costa, L.M.; de Almeida, A.A.C.; de Oliveira, G.A.L.; Costa, J.P.; de Sousa, D.P.; de Freitas, R.M.; de Almeida, R.N. Antiinociceptive and antioxidant activities of phytol in vivo and in vitro models. *Neurosci. J.* **2013**, *7*, 949452. [CrossRef]

41. Saravanakumar, K.; Vivek, R.; Boopathy, N.S.; Yaqian, L.; Kathiresan, K.; Chen, J. Anticancer potential of bioactive 16-methylheptadecanoic acid methyl ester derived from marine Trichoderma. *J. Appl. Biomed.* **2015**, *13*, 199–212. [CrossRef]

42. Saikarthik, J.; Ilango, S.; Vijayakumar, J.; Vijayaraghavan, R. Phytochemical analysis of methanolic extract of *Mucuna procumbens* by gas chromatography mass spectrometry. *Int J. Pharm. Sci. Res.* **2017**, *8*, 2916–2921. [CrossRef]

43. Kushwaha, P.; Yadav, S.S.; Singh, V.; Dwivedi, L. Phytochemical screening and GC-MS studies of the methanolic extract of *Tridax procumbens*. *Int J. Pharm. Sci. Res.* **2019**, *10*, 2492–2496. [CrossRef]

44. Ambrosi, G.D.P. Composition Based on Ethyl Ester of Linoleic acid and Triethyl Ester of Citric Acid for Topical Use in the Treatment of Seborrhea and Acne. *U.S. Patent 7,169,811*, 30 January 2007.

45. Jasim, H.; Hussein, A.O.; Hameed, I.H.; Kareem, M.A. Characterization of alkaloid constitution and evaluation of antimicrobial activity of *Solanum nigrum* using gas chromatography-mass spectrometry (GC-MS). *J. Pharmacogn. Phytotherapy* **2015**, *7*, 56–72. [CrossRef]

46. Novitasari, M.R.; Febrina, L.; Agustina, R.; Rahmadani, A.; Rusli, R. Analisis GC-MS senyawa aktif antioksidan fraksi etil asetat daun libo (Ficus variegata Blume.). *J. Sains. Kes.* **2016**, *1*, 221–225. [CrossRef]

47. Sivakumaran, G.; Prabhukumar, K.; Rao, M.; Jones, S.; Sundaram, R.L.; Ulhas, V.R.; Vijayalakshmi, N. Gas chromatography-mass spectrometry analysis of one Ayurvedic oil, Ksheerabala Thailam. *Drug Invent. Today.* **2019**, *11*, 2661–2665.

48. Akash, S.S.; Singh, S.K. Phytoconstituents estimation of Lepidium sativum L. seed extract using GC-MS spectroscopy. *World J. Pharm. Res.* **2017**, *7*, 1360–1367. [CrossRef]

49. Kaur, N.; Chaudhary, J.; Jain, A.; Kishore, L. Stigmasterol: A comprehensive review. *Int. J. Pharm. Sci.* **2011**, *2*, 2259.
50. Gabay, O.; Sanchez, C.; Salvat, C.; Chevy, F.; Breton, M.; Nourissat, G.; Wolf, C.; Jacques, C.; Berenbaum, F. Stigmasterol: A phytosterol with potential anti-osteoarthritic properties. Osteoarthr. Cartil. 2010, 18, 106–116. [CrossRef]

51. Panda, S.; Jafri, M.; Kar, A.; Mehta, B. Thyroid inhibitory, anti-oxidative and hypoglycemic effects of stigmasterol isolated from Butea monosperma. Fitoterapia 2009, 80, 123–126. [CrossRef]

52. Sushma, V.; Pal, S.M.; Viney, C. GC-MS Analysis of Phytocomponents in the Various Extracts of Shorea robusta Gaertn F. Int. J. Pharmacogn. Phytochem. Res. 2017, 9, 783–788. [CrossRef]

53. Saeidnia, S.; Manayi, A.; Gohari, A.R.; Abdollahi, M. The story of beta-sitosterol—a review. Eur. J. Med. Plants 2014, 4, 590. [CrossRef]

54. Manorenjitha, M.; Norita, A.; Norhisham, S.; Asmawi, M. GC-MS analysis of bioactive components of Ficus religiosa (Linn.) stem. J. Pharmacogn. Phytochem. 2016, 5, 173. [CrossRef]

55. Duraiswamy, A.; Shanmugasundaram, D.; Sasikumar, C.S. Evaluation of the phytochemical constituents in ADJ6, an anti-diabetic polyherbal formulation by GC-MS. J. Pharmacogn. Phytochem. 2013, 4, 99–103. [CrossRef]

56. Musaddiq, S.; Imran Shahzad, M.; Firdous, F.; Iqbal, A.; Tanveer, A.; Aslam, S.; Khakwani, S. Thiazolidines: Potential anti-viral agents against avian influenza and infectious bronchitis viruses. Vet. Res. Forum 2020, 11, 415–426. [CrossRef]

57. Greco, I.; Molehanova, N.; Holmedal, E.; Jønness, H.; Hummel, B.D.; Watts, J.L.; Håkanson, J.; Hansen, P.R.; Svenson, J. Correlation between hemolytic activity, cytotoxicity and systemic in vivo toxicity of synthetic antimicrobial peptides. Sci. Rep. 2020, 10, 13206. [CrossRef]

58. Demir, T.; Akpinar, O. Biological activities of phytochemicals in plants. Turk. J. Agric.-Food Sci. Technol. 2020, 8, 1734–1746. [CrossRef]

59. Cahlíková, L.; Breiterová, K.; Opletal, L. Chemistry and Biological Activity of Alkaloids from the Genus Lycoris (Amaryllidaceae). Molecules 2020, 25, 4797. [CrossRef]

60. Muniyandi, K.; George, E.; Sathyarayanan, S.; George, B.P.; Abrahamse, H.; Thamburaj, S.; Thangaraj, P. Phenolics, tannins, flavonoids and anthocyanins contents influenced antioxidant and anticancer activities of Rubus fruits from Western Ghats, India. Food Sci. Hum. Wellness. 2019, 8, 73–81. [CrossRef]

61. Sparg, S.G.; Light, M.E.; van Staden, J. Biological activities and distribution of plant saponins. J. Ethnopharmacol. 2004, 94, 219–243. [CrossRef]

62. Nawaz, H.; Waheed, R.; Nawaz, M. Phytochemical Composition, Antioxidant Potential, and Medicinal Significance of Ficus. Mod. Fruit Ind. 2020, 1, 20. [CrossRef]

63. Chavan, J.J.; Gaikwad, N.B.; Kshirsagar, P.R.; Dixit, G.B. Total phenolics, flavonoids and antioxidant properties of three Ceropedia species from Western Ghats of India. S. Afr. J. Bot. 2013, 88, 273–277. [CrossRef]

64. Hara, Y.; Honda, M. The inhibition of α-amylase by tea polyphenols. Agric. Biol. Chem. 1990, 54, 1939–1945. [CrossRef]

65. Matsui, T.; Tanaka, T.; Tamura, S.; Toshima, A.; Tanaya, K.; Miyata, Y.; Tanaka, K.; Matsumoto, K. α-Glucosidase inhibitory profile of catechins and theaflavins. J. Agric. Food Chem. 2007, 55, 99–105. [CrossRef]

66. Gong, L.; Feng, D.; Wang, T.; Ren, Y.; Liu, Y.; Wang, J. Inhibitors of α-amylase and α-glucosidase: Potential linkage for whole cereal foods on prevention of hyperglycemia. Food Sci. Nutr. 2020, 8, 6320–6337. [CrossRef] [PubMed]

67. Othman, L.; Sleiman, A.; Abdel-Massih, R.M. Antimicrobial Activity of Polyphenols and Alkaloids in Middle Eastern Plants. Front. Microbiol. 2019, 10, 911. [CrossRef] [PubMed]

68. Tкаченко, Г.М.; Булюн, Л.И.; Осадюкский, З.; Гончаренко, В.И.; Прокопий, А.И. Antimicrobial activity of ethanolic extract obtained from Ficus vasta Forssk. (Moraceae). Территория науки 2017, 5, 12–17. [CrossRef]

69. Kim, J.H.; Lee, J.; Kang, S.; Moon, H.; Chung, K.H.; Kim, K.R. Antiplatelet and Antithrombotic Effects of the Extract of Lindera obtusiloba Leaves. Biomol. Ther. 2016, 24, 659–664. [CrossRef]

70. Tabassum, S.; Ahmad, S.; Rehman Khan, K.U.; Tabassum, F.; Khursheed, A.; Zaman, Q.U.; Bukhari, N.A.; Alfatagh, A.; Hatamleh, A.A.; Chen, Y. Phytochemical Profiling, Antioxidant, Anti-Inflammatory, Thrombolytic, Hemolytic Activity In Vitro and In Silico Potential of Portalucaria afra. Molecules 2022, 27, 2377. [CrossRef]

71. Sowemimo-Coker, S.O. Red blood cell hemolysis during processing. Transfus Med. Rev. 2002, 16, 46–60. [CrossRef]

72. Zohra, M.; Fawzia, A. Hemolytic activity of different herbal extracts used in Algeria. Int. J. Pharm. Sci. 2014, 5, 495–500. [CrossRef]

73. Khursheed, A.; Ahmad, S.; Khan, K.-u.-R.; Tousif, M.I.; Aati, H.Y.; Ovatlarnporn, C.; Rao, H.; Khurshid, U.; Ghalloo, B.A.; Tabassum, S. Efficacy of Phytochemicals Derived from Roots of Rondeletia odorata as Antioxidant, Anticancer, Diuretic, Skin Brightening and Hemolytic Agents—A Comprehensive Biochemical and In Silico Study. Molecules 2022, 27, 4204. [CrossRef] [PubMed]

74. Baig, M.H.; Ahmad, K.; Rabbani, G.; Danishuddin, M.; Choi, I. Computer Aided Drug Design and its Application to the Development of Potential Drugs for Neurodegenerative Disorders. Curr. Neuropharmacol. 2018, 16, 740–748. [CrossRef] [PubMed]

75. Eid, E.E.; Azam, F.; Hassan, M.; Taban, I.M.; Halim, M.A. Zerumbone binding to estrogen receptors: An in-silico investigation. J. Recept. Signal. Transduct. 2018, 38, 342–351. [CrossRef] [PubMed]

76. Patil, R.; Das, S.; Stanley, A.; Yadav, L.; Sudhakar, A.; Varma, A. Optimized Hydrophobic Interactions and Hydrogen Bonding at the Target-Ligand Interface Leads the Pathways of Drug-Designing. PLoS ONE 2010, 5, e12029. [CrossRef]

77. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7, 42717. [CrossRef]

78. Lipinski, C.A. Lead- and drug-like compounds: The rule-of-five revolution. Drug Discov. Today Technol. 2004, 1, 337–341. [CrossRef]
79. Daina, A.; Michielin, O.; Zoete, V. iLOGP: A Simple, Robust, and Efficient Description of n-Octanol/Water Partition Coefficient for Drug Design Using the GB/SA Approach. *J. Chem. Inf. Model.* 2014, 54, 3284–3301. [CrossRef]

80. Duffy, F.J.; Devocelle, M.; Shields, D.C. Computational approaches to developing short cyclic peptide modulators of protein-protein interactions. *Methods Mol. Biol.* 2015, 1268, 241–271.

81. Al Azzam, K.; Negin, E.-S.; Aboul-Enein, H. ADME studies of TUG-770 (a GPR-40 inhibitor agonist) for the treatment of type 2 diabetes using SwissADME predictor: In silico study. *J. Appl. Pharm. Sci.* 2022, 12, 159–169.

82. Banerjee, P.; Eckert, A.O.; Schrey, A.K.; Preissner, R. ProTox-II: A webserver for the prediction of toxicity of chemicals. *Nucleic Acids Res.* 2018, 46, W257–W263. [CrossRef]

83. Sivanandham, V. Phytochemical techniques—A review. *World J. Sci. Res.* 2015, 1, 80–91.

84. Sembiring, E.; Elya, B.; Sauriasari, R. Phytochemical Screening, Total Flavonoid and Total Phenolic Content and Antioxidant Activity of Different Parts of Caesalpinia bonduc (L.) Roxb. *Pharmacogn. J.* 2017, 10, 123–127. [CrossRef]

85. Dilshad, R.; Ahmad, S.; Aati, H.; Al-qahtani, J.H.; Sheriff, A.E.; Hussain, M.; Ghallow, B.A.; Tahir, H.; Basit, A.; Ahmed, M. Phytochemical Profiling, In Vitro Biological Activities, and In-Silico Molecular Docking Studies of Typha domingensis. *Arab. J. Chem.* 2022, 15, 104133. [CrossRef]

86. Benarfa, A.; Gourine, N.; Mahfoudi, R.; Harrat, M.; Yousfi, M. Effect of Seasonal and Regional Variations on Phenolic Compounds of Deverra scoparia (Flowers/Seeds) Methanolic Extract and the Evaluation of Its in Vitro Antioxidant Activity. *Chem. Biodivers.* 2019, 16, e1900420. [CrossRef] [PubMed]

87. Rehman, T.; Ahmad, S.; Ghauri, A.O.; Abbasi, W.M.; Arshad, M.A. Evaluation of α-glucosidase Inhibitory Potential of Some Homeopathic Mother Tinctures. *J. Pharm. Pharm. Sci.* 2018, 6, 190–193.

88. Anyanwu, G.; Onyeneke, E.; Okoli, J.; Johannes, M.; Rehman, S.U.; Zaib, S.; Rauf, K. Pharmacological activities of a novel phthalic acid ester and iridoid glycoside isolated from the root bark of Anthocleista vogelii Planch. *Trop. Biomed.* 2019, 36, 35–43.

89. Khan, N.; Hwa, C.; Perveen, N.; Paliwal, N. Phytochemical screening, antimicrobial and antioxidant activity determination of Trigonella foenum-graecum seeds. *Pharm. Pharmacol. Int.* 2019, 7, 175–186.

90. Mahmood, A.; Mahmood, A.; Qureshi, R.A. Antimicrobial activities of three species of family mimosaceae. *Pak. J. Pharm. Sci.* 2012, 25, 203–206.

91. Shahzad, M.; Anwar, S.; Aslam, Z.; Saba, N.; Ashraf, H.; Kamran, Z. Antiviral activities of Cholistani plants against common poultry viruses. *Trop. Biomed.* 2020, 37, 1129–1140.

92. Ahmed, M.; Khan, K.-u.-R.; Ahmad, S.; Aati, H.Y.; Ovatlarnporn, C.; Rehman, M.S.-u.; Javed, T.; Khursheed, A.; Ghallow, B.A.; Dilshad, R. Comprehensive Phytochemical Profiling, Biological Activities, and Molecular Docking Studies of Pleurospermum candollei: An Insight into Potential for Natural Products Development. *Molecules* 2022, 27, 4113. [CrossRef]

93. Hemthanon, T.; Ungcharoenwiwat, P. Antibacterial activity, stability, and hemolytic activity of heartwood extract from Caesalpinia sappan for application on nonwoven fabric. *Electron. J. Biotechnol.* 2022, 55, 9–17. [CrossRef]

94. Khan, M.; Li, T.; Ahmad Khan, M.K.; Rasul, A.; Nawaz, F.; Sun, M.; Zheng, Y.; Ma, T. Alantolactone Induces Apoptosis in HepG2 Cells through GSH Depletion, Inhibition of STAT3 Activation, and Mitochondrial Dysfunction. *Biomed. Res. Int.* 2013, 2013, 719858. [CrossRef] [PubMed]

95. Idris, M.O.; Adeniji, S.E.; Habib, K.; Adeiza, A.A. Molecular Docking of Some Novel Quinoline Derivatives as Potent Inhibitors of Human Breast Cancer Cell Line. *Lab-in-Silico* 2021, 2, 30–37.

96. Laskowski, R.; Swindells, M. LigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery. *J. Chem. Inf. Model.* 2011, 51, 2778–2786. [CrossRef] [PubMed]